Obviousness

Obviousness Analysis of US Patent 7364736B2 Under 35 U.S.C. § 103

This analysis evaluates the obviousness of US Patent 7364736B2, titled "Antibodies to OPGL," by considering combinations of prior art references cited within the patent itself and assessing the motivation a person having ordinary skill in the art (POSA) would have had to combine them as of the priority date of June 26, 2001.

A. Claims Under Consideration

The core claims of US7364736B2 focus on a specific antibody, designated αOPGL-1, that binds to osteoprotegerin ligand (OPGL), as well as compositions and methods utilizing this antibody. Key aspects of the claimed invention, as described in the patent's definitions, include:

• An antibody comprising a heavy chain with an amino acid sequence as set forth in SEQ ID NO: 2 (or a fragment thereof) and a light chain with an amino acid sequence as set forth in SEQ ID NO: 4 (or a fragment thereof).
• An antibody comprising a heavy chain variable region with an amino acid sequence as set forth in SEQ ID NO: 13 (or a fragment thereof) and a light chain variable region with an amino acid sequence as set forth in SEQ ID NO: 14 (or a fragment thereof).
• An antibody comprising a heavy chain variable region with at least 90% identity to SEQ ID NO: 13 and a light chain variable region with at least 90% identity to SEQ ID NO: 14, wherein the antibody interacts with OPGL.
• Pharmaceutical compositions containing such an antibody.
• Methods of treating osteopenic disorders, inflammatory conditions with attendant bone loss, autoimmune conditions with attendant bone loss, or rheumatoid arthritis by administering the antibody.
• Methods of detecting OPGL in a biological sample using the antibody.

B. Person Having Ordinary Skill in the Art (POSA)

As of the priority date of June 26, 2001, a POSA in this field would typically possess expertise in molecular biology, immunology, protein biochemistry, and bone physiology, including practical knowledge of recombinant DNA technology, antibody engineering, and drug development for protein therapeutics.

C. Motivation to Combine Prior Art References

A POSA, acting with common sense and knowledge of the field prior to June 2001, would have been highly motivated to develop therapeutic interventions for bone-related disorders.

1. Identification of OPGL as a Therapeutic Target:

   • Prior Art: The patent itself provides significant background establishing OPGL's critical role: "Osteoprotegerin ligand (OPGL)... promotes formation of osteoclasts through binding to the receptor activator of NF-κB (RANK, also called osteoclast differentiation and activation receptor, or ODAR). Osteoprotegerin (OPG) inhibits the formation of osteoclasts by sequestering OPGL and preventing OPGL association with ODAR. The amount of OPGL associated with ODAR correlates with the equilibrium between bone deposition and resorption." Furthermore, the patent explicitly states that "Increased osteoclast activity correlates with a number of osteopenic disorders, including post-menopausal osteoporosis, Paget's disease, lytic bone metastases, and rheumatoid arthritis. Therefore, a reduction in OPGL activity may result in a decrease in osteoclast activity and may reduce the severity of osteopenic disorders."
   • Motivation to Combine: This established understanding of OPGL's direct involvement in bone resorption and its correlation with prevalent osteopenic disorders would have strongly motivated a POSA to target OPGL for therapeutic intervention. The potential for reducing OPGL activity to treat these conditions was a clear and desirable objective.

2. Availability of Established Antibody Generation Technologies:

   • Prior Art: Numerous references cited within the patent demonstrate the widespread knowledge and availability of techniques for generating therapeutic antibodies, particularly fully human antibodies, prior to the critical date:
     • The use of "transgenic animals capable of producing human antibodies" was known, as taught by "PCT Published Application No. WO 93/12227".
     • More specifically, "transgenic mice that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine, antibodies" were available for generating "human immunoglobulin molecules and antibodies," as described in "PCT Published Application No. WO 98/24893" and "Mendez et al. Nature Genetics 15:146-156 (1997)". The patent explicitly states that its antibodies "are prepared through the utilization of a transgenic mouse".
     • General molecular cloning and hybridoma methodologies were standard practice, as exemplified by "Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989))".
     • The understanding of antibody structure, including variable and constant regions, and the definition of complementarity determining regions (CDRs) and framework regions (FRs), was well-established, with references such as "Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991))" and "Chothia & Lesk J. Mol. Biol. 196:901-917 (1987)".
     • Various antibody formats, including functional fragments like Fab, Fv, and single-chain antibodies, were also known and described in references like "WO 88/01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203".
   • Motivation to Combine: Given the medical need and OPGL as a target, a POSA would have been motivated to employ these well-known and available technologies to develop a fully human monoclonal antibody against OPGL. The rationale for pursuing fully human antibodies was to minimize immunogenic responses in patients, a recognized advantage in therapeutic development at the time. The standard process would involve immunizing transgenic mice, isolating B-cells, generating hybridomas, and screening for antibodies that specifically bind to OPGL and, ideally, inhibit its osteoclastogenic activity.

D. Analysis of Obviousness for Specific Claims

While the motivation to generate an antibody to OPGL and the methods for doing so were well within the knowledge of a POSA, the specific claims of US7364736B2 present a higher bar for obviousness due to their precise sequence limitations.

• Claims Directed to Specific Antibody Sequences (SEQ ID NOs: 2, 4, 13, 14, or variants with at least 90% identity): The central aspect of claims 1, 2, and 3 is the identification of an antibody with specific amino acid sequences for its heavy and light chains, or their variable regions. In the field of antibody discovery, even when employing known immunization and screening methodologies (as described in the cited art regarding transgenic mice and hybridoma technology), the exact sequence, binding affinity, and functional characteristics of a resulting antibody are generally unpredictable. The provided prior art within the patent text describes methods of making antibodies but does not disclose or suggest the specific sequences of αOPGL-1 (SEQ ID NOs: 2, 4, 13, 14), nor does it provide a reasonable expectation that a POSA, following these methods, would predictably arrive at these particular sequences with their disclosed advantageous properties (e.g., specific binding to OPGL and inhibition of osteoclast formation and OPGL-ODAR binding at low nanomolar dissociation constants). Therefore, based solely on the prior art presented within the patent, claims explicitly tied to these specific antibody sequences or those with a high degree of identity are unlikely to be found obvious.

• Claims Directed to Pharmaceutical Compositions and Methods of Treatment/Detection: If the fundamental antibody claims (reciting SEQ ID NOs: 2, 4, 13, 14, or high identity thereof) are considered non-obvious due to the unpredictable nature of antibody discovery, then the pharmaceutical compositions comprising these novel and non-obvious antibodies, and the methods of using them for treating osteopenic disorders or for detection, would also be non-obvious. Although the therapeutic goal (targeting OPGL for bone disorders) was motivated by known biology, the specific efficacy and safety profile of the αOPGL-1 antibody, which are inherent to its unique sequence and binding properties, would not have been obvious without the discovery of the antibody itself.

E. Conclusion

A POSA would have been motivated to develop an antibody against OPGL to treat osteopenic disorders, leveraging known methods for generating fully human monoclonal antibodies. This combination of motivation and existing technology would make the concept of an anti-OPGL antibody obvious to try. However, the claims of US7364736B2 are specific to an antibody defined by particular amino acid sequences (SEQ ID NOs: 2, 4, 13, 14). The prior art references cited within the patent document, while detailing general antibody production methods, do not disclose or suggest these specific sequences or provide a reasonable expectation of predictably obtaining an antibody with the particular binding and functional characteristics of αOPGL-1. Consequently, claims reciting these specific antibody sequences, and the compositions and methods of use inherently reliant on these specific antibodies, would likely be considered non-obvious based on the information provided in the patent.